HC Wainwright Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective lifted by HC Wainwright from $200.00 to $217.00 in a research note published on Monday morning,Benzinga reports. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts also recently weighed in on JAZZ. Morgan Stanley reissued an “overweight” rating and issued a $183.00 target price (up previously from $175.00) on shares of Jazz Pharmaceuticals in a research note on Friday. Barclays reissued an “overweight” rating and issued a $200.00 price objective (up from $190.00) on shares of Jazz Pharmaceuticals in a research report on Thursday, February 27th. Piper Sandler restated an “overweight” rating and set a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, February 26th. Truist Financial increased their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. Finally, Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $130.00 to $170.00 in a report on Thursday, February 13th. One equities research analyst has rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $190.53.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $137.45 on Monday. The stock has a 50 day moving average price of $128.43 and a 200-day moving average price of $120.23. Jazz Pharmaceuticals has a one year low of $99.06 and a one year high of $148.06. The stock has a market cap of $8.35 billion, a price-to-earnings ratio of 19.36, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Insider Activity

In other news, CMO Robert Iannone sold 7,080 shares of Jazz Pharmaceuticals stock in a transaction on Friday, March 7th. The stock was sold at an average price of $138.60, for a total value of $981,288.00. Following the transaction, the chief marketing officer now directly owns 82,024 shares in the company, valued at approximately $11,368,526.40. This trade represents a 7.95 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the company’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares of the company’s stock, valued at $52,522,550.75. This trade represents a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 25,193 shares of company stock worth $3,533,122. 4.20% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. IFP Advisors Inc purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at approximately $25,000. Quadrant Capital Group LLC lifted its holdings in shares of Jazz Pharmaceuticals by 97.1% during the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company’s stock valued at $25,000 after purchasing an additional 101 shares during the last quarter. Elequin Capital LP lifted its holdings in shares of Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company’s stock valued at $26,000 after purchasing an additional 183 shares during the last quarter. CoreFirst Bank & Trust acquired a new stake in shares of Jazz Pharmaceuticals in the 4th quarter worth $28,000. Finally, Allianz SE purchased a new position in Jazz Pharmaceuticals during the 4th quarter worth $29,000. Hedge funds and other institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.